database / hormone
Desmopressin
also known as DDAVP
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 5311065. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
A vasopressin analogue: the N-terminal amine is removed and position 8 is D-arginine, so standard one-letter notation would misrepresent it.
Molecular data
| molecular formula | C46H64N14O12S2 |
|---|---|
| molecular weight | 1069.2 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | oral, intranasal, intravenous |
| PubChem CID | 5311065 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Selective V2 receptor agonist with minimal vasopressor activity.
Reported targets: V2R
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| antidiuresis | Lower Cutoffs Improve the Diagnostic Performance of Desmopressin-Stimulated … Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026 |
| von Willebrand factor release | Desmopressin for antiplatelet-associated traumatic intracranial hemorrhage: … Clinical neurology and neurosurgery 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT01078753 | Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enu | COMPLETED | PHASE3 |
| NCT02178826 | Nocturnal Enuresis and Rapid Maxillary Expansion | COMPLETED | NA |
| NCT05945420 | Adding Desmopressin to Tamsulosin for Treatment of BPH | UNKNOWN | PHASE4 |
| NCT02729766 | Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyp | COMPLETED | PHASE2, PHASE3 |
| NCT06020456 | Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A | COMPLETED | — |
Literature (8)
Lower Cutoffs Improve the Diagnostic Performance of Desmopressin-Stimulated Bilateral Inferior Petrosal Sinus Sampling for Cushing Disease: A Prospective Cohort Study — Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42336278 · DOI 10.1016/j.eprac.2026.06.005
Desmopressin for antiplatelet-associated traumatic intracranial hemorrhage: A systematic review — Clinical neurology and neurosurgery 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41863889 · DOI 10.1016/j.clineuro.2026.109400
Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma — Frontiers in medicine 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42494441 · DOI 10.3389/fmed.2026.1864843
Diagnostic performance of desmopressin stimulation test in pediatric cushing's disease — Pituitary 2025
OBJECTIVE: To evaluate the diagnostic performance of the desmopressin (DDAVP) stimulation test in pediatric patients with Cushing’s disease (CD), and to compare its accuracy and safety profile to the ovine corticotropin-releasing hormone (oCRH) stimulation test. DESIGN: A retrospective cohort study. METHODS: Pediatric patients with CD who underwent peripheral or bilateral inferior petrosal sinus sampling (BIPSS) stimulation testing with either DDAVP or oCRH were included. Patients were matched 1:1 for age, sex, and tumor size. The performance of each test was assessed by evaluating ACTH and cortisol responses and calculating test sensitivities. RESULTS: In peripheral stimulation testing, DDAVP demonstrated 96.9% sensitivity for cortisol and 81.3% for ACTH, while oCRH showed 93.8% and 96.9% sensitivities respectively (p > 0.05). Percentage change of ACTH was higher in the CRH group compar…
open access ↗ · PMID 41422341 · DOI 10.1007/s11102-025-01610-4
Desmopressin Induces Mitochondrial Fragmentation and Dysfunction in Human U87 MG Glioma Cells via CaMKII-Drp1 Signaling Pathway — Drug development research 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41527347 · DOI 10.1002/ddr.70224
Dual Aetiology of Diabetes Insipidus in Pregnancy: Vasopressinase-Mediated and Central Mechanisms — Case reports in nephrology 2026
Diabetes insipidus (DI) is a heterogeneous disorder characterised by polyuria and polydipsia due to impaired arginine vasopressin (AVP) secretion or action. We describe a 36-year-old pregnant woman who presented at 28 weeks' gestation with weakness, severe hypokalaemia from renal potassium wasting, hypernatraemia and polyuria with dilute urine. Vasopressinase-mediated DI was suspected; there was no response to AVP, but desmopressin (dDAVP) produced a rapid clinical improvement, confirming the diagnosis. However, postpartum recurrence of symptoms prompted further evaluation, with imaging suggestive of lymphocytic infundibuloneurohypophysitis, necessitating reinitiation of dDAVP. This case highlights the diagnostic complexity of DI in pregnancy and the need to remain vigilant for central causes, even when vasopressinase-mediated DI is initially suspected.
open access ↗ · PMID 42327372 · DOI 10.1155/crin/7536497
The Endothelial-Independent Effect of Desmopressin, In Vitro, on Platelet Function — Advances in hematology 2025
Platelets form the nidus around which the primary hemostatic cascade is amplified and propagated. Desmopressin (DDAVP) has been shown to enhance platelet function through interaction with the endothelium. Evidence suggests that an alternative mechanism of action may exist. We aimed to determine the effect of DDAVP on platelet function and microclotting of plasma proteins in samples from healthy volunteers. We analyzed blood samples in 20 healthy volunteers with no coagulation abnormalities. Control and test samples were drawn from each participant. DDAVP was added in vitro to test samples. All samples were subjected to PFA-200, viscoelastic (VET) and fluorescence microscopy testing. DDAVP increased TEG MA and decreased K-time in experimental samples. There was no difference between the means in the clotting times in either of the PFA-200 groups. Fluorescence microscopy examining platelet…
open access ↗ · PMID 41141991 · DOI 10.1155/ah/9928082
Reduction of hemorrhagic complications after non-focal renal biopsy with pre-procedure desmopressin administration — Diagnostic and interventional radiology (Ankara, Turkey) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41866967 · DOI 10.4274/dir.2026.263734
Related
Glucagon
hormone · 8 citations
Ghrelin
hormone · 8 citations
Oxytocin
hormone · 8 citations
Vasopressin
hormone · 8 citations
Gonadorelin
hormone · 8 citations
Kisspeptin-10
hormone · 8 citations